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Alastair H. MacLennan, MD, FRANZCOG; Suzanna C. Thompson, MBBS, FRACP; Jozef Gecz, PhDwo international expert task forcesCerebral palsy (CP) is heterogeneous with different clinical types, comorbidities, brain
imaging patterns, causes, and now also heterogeneous underlying genetic variants. Few
are solely due to severe hypoxia or ischemia at birth. This common myth has held back
research in causation. The cost of litigation has devastating effects on maternity services
with unnecessarily high cesarean delivery rates and subsequent maternal morbidity and
mortality. CP rates have remained the same for 50 years despite a 6-fold increase in
cesarean birth. Epidemiological studies have shown that the origins of most CP are prior
to labor. Increased risk is associated with preterm delivery, congenital malformations,
intrauterine infection, fetal growth restriction, multiple pregnancy, and placental ab-
normalities. Hypoxia at birth may be primary or secondary to preexisting pathology and
international criteria help to separate the few cases of CP due to acute intrapartum
hypoxia. Until recently, 1-2% of CP (mostly familial) had been linked to causative mu-
tations. Recent genetic studies of sporadic CP cases using new-generation exome
sequencing show that 14% of cases have likely causative single-gene mutations and up
to 31% have clinically relevant copy number variations. The genetic variants are het-
erogeneous and require function investigations to prove causation. Whole genome
sequencing, fine scale copy number variant investigations, and gene expression studies
may extend the percentage of cases with a genetic pathway. Clinical risk factors could
act as triggers for CP where there is genetic susceptibility. These new findings should
refocus research about the causes of these complex and varied neurodevelopmental
disorders.
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sation in 19991 and 2003.2 In 2014, the
American Congress of Obstetricians and
Gynecologists and the American Acad-
emy of Pediatrics, with many interna-
tional consultants, updated these reports
but chose to focus on neonatal enceph-
alopathy and a variety of neurological
outcomes rather than discuss CP causa-
tion speciﬁcally and did not directly
address the ramiﬁcations of litigation
following a diagnosis of CP.3 Recent
ﬁndings published after the 2014 report
have identiﬁed likely causative genetic
variants associated with CP cases and
this review contributes to updating
clinicians.
CP is a heterogeneous condition
with multiple causes; multiple clinical
types; multiple patterns of neuropa-
thology on brain imaging; multiple
associated developmental pathologies,
such as intellectual disability, autism,
epilepsy, and visual impairment; and
more recently multiple rare pathogenic
genetic variations (mutations). CP
would be better named “the cerebral
palsies” given that within the CP clinical
spectrum there are many causal path-
ways and many types and degrees of
disability. These various pathways and
etiologies have each resulted in a
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DECEMBER 2015 Ampopulation data are available.1 It remains
around 2-2.5/1000 births. Although
there have been small statistical ﬂuctua-
tions in the CP rates among children
born preterm, the rates of CP at term
remain stable.4 New interventions such
as head or body cooling in selectedthe University of Adelaide, Adelaide, Australia
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, Australia.
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Expert Reviews Obstetrics ajog.orgcases with acute hypoxia have yet to
signiﬁcantly lower overall rates. Only
a small percentage of cases are associ-
ated solely with acute intrapartum
hypoxia.5-8 Despite this, many cases are
mislabeled as due to birth asphyxia.
Birth asphyxia
“Birth asphyxia” is an outdated term that
may wrongly convey that a baby born
with signs of fetal and neonatal
compromise must have undergone an
acute hypoxic event in late labor and/or
birth. These clinical signs may also be
present when there has been much
longer-standing fetal compromise with
possible secondary hypoxia near de-
livery.1 Similarly, the term “hypoxic
ischemic encephalopathy” has been
replaced by the term “neonatal enceph-
alopathy” as the large majority of
newborn infants showing signs of en-
cephalopathy does not have objective
proof of acute hypoxia or ischemia at
birth, but have other causes of perinatal
compromise such as infectious or ge-
netic.9 Of note, only 13% of term babies
who exhibit neonatal encephalopathy
are later diagnosed with CP.10
At birth, nonspeciﬁc signs of fetal
compromise such as meconium-stained
amniotic ﬂuid, nonreassuring fetalTABLE 1
International consensus criteria to de
Essential criteria to show presence of hypoxia a
1. A metabolic acidosis at birth (pH <7.00 and
2. Early moderate to severe neonatal encephal
3. Cerebral palsy of spastic quadriplegic or dys
4. Exclusion of other identifiable causes of ce
antepartum hemorrhage, prematurity, intrau
Five nonspecific criteria collectively point towar
If most are met they suggest timing of neuropath
criteria are:
5. Sentinel (signal) hypoxic event sufficient to ca
uterus.
6. Sudden sustained fetal heart rate bradycard
7. Apgar score <4 after 5 min.
8. Signs of multisystem failure in neonate.
9. Early (within 5 d) neuroimaging signs of ede
In 2003, American College of Obstetricians and Gynecologists/Am
Task force agreed with 1999 task force criteria and added fourth e
cause was to be presumed. Also acute de novo intrapartum even
accepted evidence of severe metabolic acidosis from arterial um
resuscitation.
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780 American Journal of Obstetrics& Gynecologyheart rate patterns, low Apgar scores,
and neonatal encephalopathy could all
be associated with either acute intra-
partum timing or chronic long-standing
timing of the pathologies (ie, beginning
before labor and during pregnancy).
The same signs can be caused by not
only hypoxia and/or ischemia, but also
by other factors such as infection,
placental and umbilical vessel throm-
bosis, or an altered fetal inﬂammatory
response.1 Very recent studies suggest
that many cases of CP are associated
with genetic alterations (mutations) that
may either directly cause CP or
contribute to susceptibility to CP.11,12 As
yet, they are not detectable antenatally or
preventable.
International consensus criteria to
identify severe acute intrapartum
hypoxia
There is now increasing evidence that
babies given a “birth asphyxia” label due
to clinical signs such as low Apgar scores
often do not have primary asphyxia.13,14
Many such babies are in ill health due
to longer-standing problems. Acute or
chronic hypoxia can cause a metabolic
acidosis in the blood of the newborn and
this has to be objectively measured in





rebral palsy, eg, coagulation or genetic disorders
terine growth restriction, tight nuchal cord, complic
d acute or chronic causes of hypoxia.
ology near delivery. If most are not met they suggest
use sudden severe hypoxia in healthy fetus, eg, cord
ia from that event.
ma and intracranial hemorrhage.
erican Academy of Pediatrics Cerebral Palsy Expert Task Force2 updat
ssential criterion was necessary, ie, that no major chronic cause of neu
t severe enough to be associated with cerebral palsy would cause Apg
bilical samples taken at birth, as blood gases can improve or worsen in
J Obstet Gynecol 2015.
DECEMBER 2015ascertain if clinically severe hypoxia is
contributing to the poor condition of
the newborn.Whenmetabolic acidosis is
proven to be present, this is evidence of
either acute hypoxia beginning in labor
or chronic hypoxia (ie, long-standing
compromise in pregnancy beginning
before labor). Secondary asphyxia in la-
bor is not necessarily the initial cause of
the brain injury but may be a subsequent
result of the established neuropatholog-
ical process. International consensus
criteria have been published and reﬁned
to help deﬁne cases where neuropa-
thology may have become established
only in labor and birth.1,2 These 9 cri-
teria have helped recognize the few cases
of severe de novo acute intrapartum
hypoxia (Table 1). These criteria, as a
group, have been well veriﬁed.15 The
ﬁrst 4 essential criteria have a high
but not individually perfect correlation
(94-100%) in acutely asphyxiated neo-
nates. The 5 nonspeciﬁc timing criteria
were individually less predictive, but
were to be assessed together, and
their consensus helps understand the
likely timing of the neuropathology. In
2014, a third consensus statement
similarly examined neonatal encepha-
lopathy, rather than CP, and largely
supported the criteria that deﬁne aa potential cause of cerebral palsy
, infectious conditions, intrapartum pyrexia,
ations of multiple pregnancy.
longer-standing pathological process. These
prolapse, antepartum hemorrhage, ruptured
ed 1999 criteria1 on basis of published evidence to that date.
ropathology should be present if intrapartum acute asphyxial
ar scores to remain at3 after 5 min of birth. Lastly, it only
first hour depending on successful or problematic neonatal
FIGURE 1
Six-fold increase in cesarean delivery without change in CP prevalence
Prevalence of CP/1000 births compared with cesarean rates over the past 50 years.68
CP, cerebral palsy.
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ical event.3
Intrapartum cardiotocography
It is important to understand the great
limitations of intrapartum electronic
fetal heart rate monitoring, and in
particular its inability to reduce or pre-
vent CP. Cochrane systematic reviews of
relevant randomized controlled trials
of electronic fetal heart rate monitoring
show no reduction in CP rates with its
use compared to intermittent ausculta-
tion of the fetal heart.16 Continuous
electronic fetal heart rate monitoring
was introduced in the 1960s, without
prior testing in randomized controlled
trials, partly in the belief that it would
allow early recognition of acute fetal
compromise and in particular hypoxia.
It was hoped that this would reduce
intrapartum brain injury, because of
the long-standing assumption and belief
that many cases of CP were due to
preventable acute hypoxia beginning
in labor. However, fetal heart rate is a
very indirect and poor measure of past
and present fetal brain function and
damage.
Intrapartum cardiotocography has a
very high false-positive rate and with the
pressures of obstetric litigation in many
countries, birth attendants and espe-
cially individuals giving private care,
who cannot be in continuous atten-
dance, often opt for cesarean delivery.
Defensive obstetrics, often in response
to uncertain cardiotocographic inter-
pretation, has contributed to a large in-
crease in cesarean delivery rates without
a change in CP rates (Figure 1). The
quantum of claims following CP is very
high in countries such as the United
States, Australia, and the United King-
dom. English health trusts paid £482
million for “maternity negligence” co-
verage in 2012 through 2013 equating
to a ﬁfth of all spending on maternity
services.17 A small group of expert wit-
nesses for the plaintiff regularly opine
that the cause of the CP was birth as-
phyxia that was recognizable in labor
and preventable by earlier delivery. To
challenge such nonevidence-based opi-
nion, it is time for obstetric colleges and
academic scientiﬁc societies in this ﬁeldto spell out that cardiotocography: (1)
cannot detect the timing of the onset of
neuropathology; (2) cannot determine
a time when it would be reversible
and then irreversible; and (3) cannot be
used to determine that earlier delivery
by cesarean delivery “on the balance of
probabilities” would have prevented the
CP outcome.18 Courts should ﬁnd that
junk science is inadmissible in deter-
mining CP causation and prevention.19
Clinical risk factors for CP
during pregnancy
There is increasing scientiﬁc evidence
that CP is usually associated with long-
standing intrauterine pathology like
genetic mutations and probable envi-
ronmental triggers such as bacterial
and viral intrauterine infection, intra-
uterine growth restriction (IUGR),
antepartum hemorrhage, tight nuchal
cord, and threatened miscarriage.20 It
can be difﬁcult to pinpoint adverse
pregnancy factors in retrospect, many
years after birth, that individually or
together might have triggered the path-
ways to the neuropathology.
Preterm delivery
Preterm delivery is a major risk factor
for CP and is seen in approximately
35% of all cases, and the risk increases
the lower the viable gestational age.20,21
The risk of subsequent CP <33 weeks’
gestation is 30 times higher than amongDECEMBER 2015 Amthose born at term and is approximately
70/1000 deliveries.7 The prevalence of
CP is highest in children born <28
weeks’ gestational age (111.8/1000
neonatal survivors; 82.25/1000 live
births) and declines with increasing
gestational age, being 43.15/1000 live
births between 28-31 weeks, 6.75/1000
between 32-36 weeks, and 1.35/1000 for
those born >36 weeks.22 The mecha-
nisms and pathways to the neuropa-
thology of CP may differ from term
babies, although associated risk factors
such as infection, genetic variations,
and growth restriction are likely to
contribute.
Coexisting congenital anomalies
The prevalence of congenital anomalies
in children with CP is much higher
than in the general population and most
are cerebral, such as schizencephaly
and hydrocephaly.23 Noncerebral mal-
formations are also increased, such as
cardiac, musculoskeletal, and urinary.24
In a case-control study of 494 singleton
infants with CP born >35 weeks’ gesta-
tion included on the Western Australian
Register of Developmental Anomalies
and 508 matched controls, birth defects
(42.3%) and fetal growth restriction
(16.5%) were more strongly associated
with CP than potentially asphyxial
birth events (8.5%) and inﬂammation
(4.8%).25 Birth defects had the largest
association with CP in that study in botherican Journal of Obstetrics& Gynecology 781
Expert Reviews Obstetrics ajog.orgterm and preterm babies. Growth-
restricted babies with birth defects were
at special risk of CP. The strong associa-
tion with congenital abnormalities sug-
gests possible genetic factors although
congenital infections, nutritional disor-
ders, and teratogenic inﬂuences all
contribute to maldevelopment.
Intrauterine infection
There are many probable antenatal
causes of white-matter damage and
risk factors for CP (Table 2). Some of
these causes include damage acquired
following perinatal infection (ie, ma-
ternal infection that affects the fetus and
its brain during pregnancy and/or labor
or in the neonatal period).26 Viral or
bacterial infections may be relatively si-
lent during pregnancy and not recog-
nized clinically at the time and the
placenta is often discarded without his-
tological examination for inﬂammatory
pathology. Maternal reports of fever or
infection during pregnancy are signiﬁ-
cantly associated with an increased
risk of CP in our recent large Australian
case-control study.27 Evidence of intra-
uterine infection, evidenced by histo-
logical chorioamnionitis in the placenta
and membranes or intrapartum pyrexia,
is associated with a 4-fold increase in
CP (odds ratio 3.8; 95% conﬁdence in-
terval, 1.5e10.1) in term infants.28
Abnormal fetal inflammatory
response and thrombophilia
Another possible related cause and
mechanism of CP is an abnormalTABLE 2
Epidemiologic and genetic risk facto
Preterm delivery
Coexisting congenital anomaly (maldevelopmen
Probable genetic causes
Bacterial and viral intrauterine infection
Altered fetal inflammatory or thrombophilic resp
Fetal growth restriction
Higher-order pregnancy, risk greater with mono
Tight nuchal umbilical cord
Prolonged shoulder dystocia
Placental pathology, eg, chorioamnionitis, funisi
Inborn errors of metabolism
Male:female ratio 1.3:1
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782 American Journal of Obstetrics& Gynecologyinﬂammatory response in the fetus and
the neonate.29,30 An excessive or abnor-
mal rise in cytokines (due to genetic
predisposition or mutations) following
infection and an inﬂammatory response,
which is part of the body’s normal defense
mechanism against infection or toxins,
may cause an autoimmune type of
attack on the fetal or neonatal developing
nerve cells. The prematurely delivered
baby’s immature brain is even more
vulnerable to these proinﬂammatory
cytokines. In previous genetic associa-
tion studies, hereditary thrombophilia
(the methylenetetrahydrofolate reductase
cC677T mutation and the prothrombin
gene c20210G>A variant) and some
cytokine polymorphisms (interleukin-6,
interleukin-8, tumor necrosis factor, and
mannose binding lectin) were associated
with an increased risk of CP.31,32
Intrauterine growth restriction
IUGR is associated with up to a 10- to
30-fold increase in the risk of CP at
term.20,33 In particular, spastic CP in-
creases with the degree of fetal growth
restriction. Our large epidemiological
study of Australian children and normal
controls clearly conﬁrms IUGR as a
major risk factor for CP.27 The risk of CP
increased from values <20th percentile
and the risk escalated greatly in babies
under the third percentile (Figure 2).
IUGR can be due to many known and
unknown causes, but usually reﬂects
poor implantation and poor placenta-
tion from genetic, anatomical (eg, uter-
ine ﬁbroids, congenitally abnormalrs for cerebral palsy
t)
onse (perinatal stroke)
zygosity and in vitro fertilization
tis, villitis
J Obstet Gynecol 2015.
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pathological (eg, preeclampsia, diabetes,
systemic lupus) causes. IUGR increases
in late pregnancy when growth velocity
should be at its greatest and fetal demand
may outstrip placental and maternal
supply. This usually creates an asym-
metrical growth restriction where the
baby is lighter than its length suggests.
This gives a low ponderal index (birth-
weight/length3  100) and can suggest
unsuspected late growth restriction.34
Use of the ponderal index and custom-
ized weight for gestation charts improve
the recognition of growth restriction at
birth and the risk of subsequent CP.35
When IUGR is suspected during
pregnancy there are no published ran-
domized quality data to suggest that
earlier delivery reduces the risk of CP.
It is not possible to detect or predict
when in pregnancy the neuropathology
of CP begins, becomes established,
and is irreversible. A growth-restricted
fetus may show signs of possible fetal
compromise during labor. This can
reﬂect reduced capacity/reserves to
withstand the normal stresses of labor,
established neurological and ongoing
fetal compromise, or both. It is not
possible to distinguish between these
timings.
Multiple pregnancy
Multiple pregnancy increases CP risk
2-fold in each twin. In vitro fertiliza-
tion twins each have >4-fold risk
(9.5/1000), giving another reason to
encourage single embryo transfer in
fertility programs.36
Tight nuchal cord at delivery
Potentially chronic asphyxiating condi-
tions, chieﬂy a tight nuchal cord, in-
crease the risk of spastic quadriplegic
CP. A large population-based study,
noted that a tight umbilical cord around
the fetal neck, requiring cutting before
delivery of the shoulders, or a true um-
bilical knot increased the risk of spastic
quadriplegia 18-fold (odds ratio, 18;
95% conﬁdence interval, 6.2e48).37
Tight cords may prevent or slow descent
of the head into the pelvis in late preg-
nancy and may cause intermittent
ischemia and hypoxia during Braxton
FIGURE 2
Cerebral palsy risk increases with severity of fetal growth restriction
Customized birthweight centile and cerebral palsy (CP).27
CI, confidence interval.
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Further cord constriction and delay is
likely in the second stage of labor,
causing acute on chronic hypoxic signs.
Prolonged shoulder dystocia
This can be difﬁcult to anticipate and
manage. If severe it can lead to fractures,
stillbirth, or severe acute hypoxia. Pre-
disposing causes to CPmust be excluded
and arterial cord gases showing a severe
metabolic acidosis are needed to infer
that this acute sentinel event caused the
CP.
Placental pathology
Chorioamnionitis, funisitis, and in pa-
rticular necrotizing funisitis all are evi-
dence of infection predating labor, and
are associated in all epidemiological
studies with an increased risk of
CP.28,29,38 Chronic villitis, large infarcts,
fetal thrombotic vasculopathy, and
meconium-associated fetal vascular ne-
crosis are all risk factors for subsequent
CP or neurological impairment.39 The
increased prevalence of placental and
cord abnormalities in children subse-
quently diagnosed with CP underlines
the importance of requesting placental
histology and cord arterial gases in all
cases where the baby is delivered in
poor condition.13
Viral infection in pregnancy
Studies using polymerase chain reaction
techniques on neonatal blood spots from
CP cases and controls show increased CP
risk after both Cytomegalovirus and
Epstein-Barr virus infections during
pregnancy.40 Epidemiological studies
do not associate upper respiratory in-
fections during pregnancy with CP,
but some studies have associated in-
creased risk with bacterial urinary tract
infections.26,41
Treatable and nontreatable inborn
errors of metabolism presenting
as CP
A recent systematic review of the world
literature has described 67 treatable
inborn errors of metabolism (IEMs)
belonging to 13 different biochemical
categories and >20 currently untreat-
able IEMs with symptoms that mimicCP.42 Individually, these inborn errors
of metabolism IEMS are all very rare
(1:10,000-1:250,000). Together, they
may contribute to only 0.1-0.2% of cases
of CP, but are important as many can be
treated or controlled. New-generation
sequencing is likely to facilitate new
IEMs that exhibit CP-like symptoms.
Genetic causes of CP
Genetic causes have long been suspected
because of the link with congenital
malformations, and increased risk in
consanguineous families and mono-
zygotic twins.43 Although initially candi-
date gene association studies suggested
that several genes may be linked to
CP, the power of these studies was low
and multiple comparisons weakened
their validity.31,32 A multivariable analy-
sis of 39 candidate genes from single-
nucleotide polymorphism association
studies with CP was conducted with sta-
tistical allowance for type I error. This
study did not statistically conﬁrm previ-
ous gene associations in CP causation.44
A recent study showing an association
with the apolipoprotein E e3 allele spec-
ulated that those with the APOEe2 and
APOEe4 alleles were more likely to die in
utero.45
Previous estimates have suggested
that the contribution of genetic vari-
ants to the burden of CP was aboutDECEMBER 2015 Am2%.46 With the advent of affordable
new-generation DNA sequencing the
focus of genetic investigations in CP
shifted from gene association studies
to the identiﬁcation of the likely
causal variants. Several of the currently
known single-gene causes of CP have
been identiﬁed through study of fam-
ilies with 2 individuals with CP, such
as the KANK1, AP4MI, and GAD1 gene
mutations.47-50 Until recently, though,
only a few singleton cases with CP
had been resolved. Cases with auto-
somal recessive, rare autosomal domi-
nant, or X-linked forms have also been
described.51
One example of a success of an iden-
tiﬁcation of a novel gene and muta-
tion leading to CP is the ZC4H2 gene.
With the aid of whole exome sequencing
(WES) or X-chromosome exome se-
quencing across a large set of families
with different clinical presentations,
primarily intellectual disability, mu-
tations have been identiﬁed in the
zinc-ﬁnger gene ZC4H2 in 5 different
families and at least 3 singletons. In-
terestingly, the clinical presentations
of ZC4H2 gene mutations are broad
and variable within and between fam-
ilies, including CP spasticity pheno-
type and shared comorbidities, namely
intellectual disability and seizures.52
Functional studies of these variantserican Journal of Obstetrics& Gynecology 783
TABLE 3
Results of WES in 98 case-parent CP trios
Results
57 of cases had validated genetic variants
14% were deemed likely to be pathogenic by strict bioinformatic criteria
8 were novel genes in CP
5 were known disease genes with CP as a new phenotype
Another 44% had variants of lesser bioinformatic priority
All of these variants require function tests to refute or help confirm pathogenicity
Putative causative variants in 98 sporadic cerebral palsy (CP) families.12
X-Chr, X chromosome; OMIM, Online Mendelian Inheritance in Man register (Johns Hopkins University, Baltimore, MD; http://
www.omim.org/); WES, whole exome sequencing.
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loss of the ZC4H2 protein function
caused abnormal swimming and im-
paired alpha-motoneuron development.
In mouse hippocampal neurons, tran-
siently expressed ZC4H2 protein local-
ized to the postsynaptic compartment of
excitatory synapses and loss of ZC4H2
function led to reduced dendritic
spine density and impaired central and
peripheral synaptic plasticity.52 Such
follow-up functional studies are essential
to conﬁrm CP pathogenicity and better
understand molecular pathways involv-
ed and provide explanation for complex
and variable clinical presentations.FIGURE 3
DNA variant and gene prioritization f
OMIM, Online Mendelian Inheritance in Man register (Johns Hopkins
MacLennan. Cerebral palsies: new insights and causes. Am J O
784 American Journal of Obstetrics& GynecologyWES is indeed a powerful tool to
identify efﬁciently the likely causative
genetic variant. In particular, sequen-
cing of multiple family members can
reduce the number of candidate DNA
variants to 1 or 2 and thus also lead to
timely and precise diagnosis. This was
nicely demonstrated in a family initially
diagnosed with a CP-like movement
disorder, where 3 members with “he-
reditary benign chorea” were identiﬁed
to carry a 7-base pair deletion in exon
1 of the NKX2-1 gene. The mutation
is predicted to lead to a frame shift
in protein translation and subsequent
premature termination of NKX2-1or pathogenicity
University, Baltimore, MD; http://www.omim.org/).
bstet Gynecol 2015.
DECEMBER 2015messenger RNA translation and NKX2-1
functional haploinsufﬁciency.53
Recent investigations of genetic caus-
es in a large cohort of singleton CP cases
using WES shows that the proportion
of the cases carrying plausible genetic
mutation is much larger than previously
thought. At least 14% of nearly 200
singleton cases with CP studied have
been found to have a plausible genetic
mutation, de novo or inherited12 (Table
3). A further 44% had candidate variants
that are yet to be resolved in regard to
their causation of the CP. The percentage
of cases with a genetic mutation is likely
to rise as larger cohorts are studied,
new CP genes are discovered, and
whole genome sequencing is routinely
performed.
Better resolution of the genetic diag-
nosis will also be achieved using sophis-
ticated formulae for disease gene and
disease DNA variant prioritization such
as the Residual Variation Intolerance
Score54 and Combined Annotatione
Dependent Depletion,55 respectively
(Figure 3). Contribution of the dosage
imbalances or copy number variants
(CNVs) is yet to be fully assessed. Ten
of 50 singleton CP cases had potential-
ly relevant CNVs in our pilot study.56
However, all these CNVs were inherited
from a healthy parent suggesting another
genetic or environmental contributing
factor. Such inheritance pattern is not
unusual for other neurodevelopmental
disorders like intellectual disability or
autism. In a new study from Israel, 16 CP
cases of 52 cases (31%) of unknown eti-
ology had CNVs that were likely to be
pathogenic and 12 of these were de
novo.57 Currently, the combination of
14% of cases with individually likely
pathogenic point mutations found by
WES and 20-31% with CNVs of interest
gives a potential genetic contribution to
causation in up to 34-45% of CP cases.
This new study also reinforces the con-
clusions of previous CNV56 and WES12
studies suggesting considerable genetic
heterogeneity of CP.
Sophisticated functional studies are
required to validate genetic ﬁndings.
A plethora of approaches using in
silico tools; animal models like zebra-
ﬁsh, fruit ﬂy, or mice; or stem cells
FIGURE 4
Zebrafish ZC4H2 knockdown compromises movement and motoneuron
development
A, Outgrowth of spinal cord motoneurons and formation of neuromuscular junctions (arrows)
are morphologically affected in ZC4H2 morphants, but not in controls. B, Superimposed images
of tail movement at 48 hours postfertilization. Compared to animals injected with control MOs,
ZC4H2-knockdown zebrafish (lower) show weak swimming contraction.
MO, morpholino oligonucleotide.
Adapted from Hirata et al.52
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stem cells) will greatly assist in these
pursuits58,59 (Figure 4). In this example,
the ZC4H2 mutation impairs neuronal
plasticity and movement control in the
zebraﬁsh model.
It is likely that at least a proportion
of the CP cases will be explained by more
complex genetics and not just single
major gene effect. Our WES study iden-
tiﬁed likely causative genetic contribu-
tions to CP. Variants that may predispose
to CP by interacting with environmental
triggers have yet to be identiﬁed. Predis-
posing variants would likely be oligogenic
or polygenic and thus additive in nature
and would require genomewide associa-
tion studies and gene-environment in-
vestigations on a large sample of CP cases
and controls. Such variants would in-
crease the risk of a CP phenotype and not
be deterministic of CP. Established envi-
ronmental risk factors for CP, such as
IUGR, infection, and prematurity, may
interact with predisposing genetic vari-
ants and potentiate and multiply the
chance of a CP outcome.
Male sex
In most epidemiological studies, males
are more at risk of CP than females:
1.3:1.5,7,27 Recessive X-linked chromo-
some variants may contribute to this
difference and males may be more
vulnerable to genetic mutation (point
or copy number) than females.60
Interventions to prevent CP
Over the last 50 years, CP rates have
remained the same despite major ad-
vances in obstetrics and neonatology
including a 6-fold increase in cesarean
delivery rates and liberal induction pol-
icies to reduce postmaturity (Figure 1).
Currently there are no proven obstetric
clinical policies that have been shown to
reduce CP in term babies, other than
head cooling in selected cases. In cases
with neonatal encephalopathy, early
neonatal head cooling reduces the risk of
death or major neurological disability in
1 of 6 of these selected cases treated.61
Policies that have been ineffectual in-
clude elective cesarean delivery, earlier
emergency delivery in pregnancy, and
electronic fetal heart rate monitoring.Although prospective randomized con-
trol trials are not ethically possible,
all observational studies show no pro-
tective effect of elective or emergency
cesarean delivery for CP outcome (as
opposed to neonatal encephalopathy,
which is a different clinical diagnosis
with often different causes).62 It has not
been shown that earlier rapid delivery
of a fetus by cesarean delivery, when a
compromised fetus is ﬁrst suspected
during labor in an obstetric hospital,
changes the risk of a CP outcome.
Audits of decision-to-delivery reaction
times often do not show that cesareanDECEMBER 2015 Amdelivery can always practically and
safely be achieved in<30minutes or that
rapid delivery changes the neurological
outcome.63
In very preterm infants maternal
magnesium sulfate infusion in labor re-
duces slightly the risk of CP. Numbers
needed to treat to prevent 1 case ¼ 63.64
CP classification by causation
There is considerable debate in the in-
ternational literature whether to remove
the diagnosis of CP in nonprogressive
cases that fulﬁll the clinical deﬁnition,
when a genetic cause is found.65 Recenterican Journal of Obstetrics& Gynecology 785
Expert Reviews Obstetrics ajog.orgresearch highlights the importance of
rigorous clinical assessment of all cases,
with appropriate investigations, to avoid
misdiagnosis (eg, progressive disorders)
and to identify etiology whenever pos-
sible. One useful tool is the Develop-
mental BrainDisorders Database (DBDB:
https://www.dbdb.urmc.rochester.edu/
home), which is a publicly available,
online-curated repository of genes, phe-
notypes, and syndromes associated with
neurodevelopmental disorders.66 This
database curates the genes associated with
neurodevelopmental phenotypes, assem-
bles ontology of these phenotypes from a
number of sources, and develops a system
of levels of evidence for gene-phenotype
associations.
The CPs share a common clinical sign
of nonprogressive dysfunction of pos-
ture and movement control but not a
common diagnosis. Although there are
many CP types, many causes, and now
many associated pathogenic genetic
variants, it is probably not advisable to
change the clinical diagnosis of CP made
by specialist pediatricians in cases that
fulﬁll the clinical deﬁnition, when a
speciﬁc cause is later apparent. The
diagnosing clinician should give a full
description of the type of CP, and any
known underlying etiological factors.
The clinical diagnosis of CP and its 5
grades of disability deﬁne the clinical
problem and requirements for care.
Removing the label of CP would artiﬁ-
cially lower the prevalence of CP in
speciﬁc CP registries, making historical
comparisons difﬁcult and the effect of
new preventative interventions such as
early detection and/or gene therapy
difﬁcult to measure. Also disability
pension schemes can be based on the
diagnosis of CP and level of disability.
Such no-fault insurance pension sc-
hemes are efﬁcient, cheaper, and much
more equitable for all families with a
CP child rather than the current iniqui-
tous de facto social welfare system of
suing insured maternity services and
their staff.67 Future screening of current
CP cases with a panel of known candi-
date genes proven in function studies
or likely to cause CP (targeted gene
resequencing) should reduce inappro-
priate litigation and help to diminish its786 American Journal of Obstetrics& Gynecologydeleterious effect on the maternity
services.
Future clinical applications
The long-term goal is the prevention of
CP. Targeted screening of parents for
inherited causative genes, embryo pre-
implantation screening, or antenatal
diagnostic DNA techniques in early
pregnancy are possibilities in the near
future. Gene silencing and gene therapy
remain a more distant and exciting
prospect in the prevention of some of the
CPs.
Conclusion
The long-held belief that most or
many cases of CP are due to trauma or
asphyxia around the time of birth and
that earlier intervention can prevent the
neuropathology is not evidence based,
has held back research into other path-
ways, and has fuelled unwarranted liti-
gation that has had an untoward effect
on modern maternity care and maternal
outcomes. While it is possible that a se-
vere acute de novo metabolic acidosis
could be a rare primary cause of CP, or
that intrapartum hypoxia could be a
continuing or secondary cause of CP, the
great likelihood is that, with the excep-
tion of uncommon causes in infancy, the
pathways to the neuropathology of CP
usually begin well before labor and often
in earlier pregnancy. It is now important
to consider possible genetic causes that
may directly, or through genetic sus-
ceptibility, trigger different pathways to
different neuropathologies that share the
common clinical trait of a nonprogres-
sive movement disorder diagnosed as CP
(Video). In the near future, it will be
possible to test for many of the putative
or validated genes that have been asso-
ciated with CP to date. This panel of
different pathogenic genetic variations
contributing to the CP spectrum is very
likely to grow over the next decade, and
should open a new direction into the
causes of CP and challenge previous
medicolegal assumptions about the
culpability of the accoucheur. -
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